October 22, 2020 Great event; I learned a lot and will have a discussion with my doctor about participating in a trial. It was excellent, and the website is very easy to use. I learned that the medicines you take for lupus are not designed for the disease while the ones you take in a […] READ MORE
July 27, 2020 The Lupus Research Alliance congratulates 2018 Lupus Insight Prize recipient Betty Diamond, MD and the Feinstein Institutes for Medical Research on being awarded $15 million from the National Institute of Allergy and Infectious Disease to study brain dysfunction linked to lupus. Dr. Diamond will use the five-year grant to study a receptor […] READ MORE
December 18, 2019 The Lupus Research Alliance (LRA) welcomes additional positive results published today in the New England Journal of Medicine online edition from AstraZeneca’s Phase 3 TULIP-2 trial studying the investigational biologic anifrolumab as a treatment for systemic lupus erythematosus (SLE or lupus). The new study provides further details showing that anifrolumab, which targets […] READ MORE
October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] READ MORE
September 18, 2019 The LRA is pleased to share that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to obinutuzumab (Gazyva®) for adults with lupus nephritis – the most common complication of lupus. The FDA’s designation aims to speed up the development and review of drugs intended to treat a serious condition […] READ MORE
MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019. Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […] READ MORE
April, 2019 As our name implies, the Lupus Research Alliance aims to forge partnerships and bring other players to the table to better understand and treat lupus — and our latest venture holds the promise of a new therapy. We — and our affiliate, Lupus Therapeutics — are about to collaborate with Takeda Pharmaceutical Company […] READ MORE
A new study funded by the Lupus Nephritis Trials Network with support from the Lupus Research Alliance has proposed a set of standardized measures that promise to improve the way clinical trials in lupus nephritis (LN) are structured and how clinical researchers report their results. The findings will also help researchers in their search for […] READ MORE
New York, NY– March 1. The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916). The national study will be conducted in 20 research centers throughout the country, many […] READ MORE
NEW YORK, NY. February 19. Pieces of bacteria that escape from the intestines may trigger lupus and associated disease flares in some patients, according to a new study partly funded by the Lupus Research Alliance. These findings may allow disease treatment with probiotics or diets that alter the mix of bacterial species in the intestines. […] READ MORE
In 2018 the Lupus Research Alliance has taken daring chances, pursued bold initiatives, and made tremendous strides! We truly are breaking through on many pioneering fronts of lupus research — thanks to the unwavering generosity of donors at all levels of support. Throughout the year, the brilliant scientists we brought to the table ushered in […] READ MORE
December, 2018 An innate — and lifelong — curiosity about the most complex, unresolved questions in medicine has served John D. Mountz, MD, PhD, from the University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, well. For the past three decades he has made significant strides in piecing together some of the most […] READ MORE
